NPPA Revises Prices for Over 1,000 Anti-Cancer Drugs to Curb High Markups
The National Pharmaceutical Pricing Authority (NPPA) has revised the maximum retail prices (MRP) for 1,085 anti-cancer drugs, effective November 9, following a trade margin rationalisation announced on October 17. This includes 137 non-scheduled medicines whose trade margins were capped at 30%, aiming to reduce excessive markups that previously reached up to 700%. The price cuts, averaging around 38% and reaching up to 70% for some drugs, respond to concerns over high cancer treatment costs amid India's growing cancer burden. State authorities like Assam are enforcing compliance through inspections and penalties.
First-hand measurement across 7 sources
We measured how 7 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (48/100). Lens Score 50/100.
Outlets measured: economictimes, news18, northeastnow, indiatoday, timesnow, mint, thehindu. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment ranged widely across outlets — from 38/100 to 75/100 — a sign the coverage itself was contested, not just reported.
Coverage timeline
thehindu broke this story on 2 Nov, 07:45 am. Other outlets followed.